How to make your money go further

GlaxoSmithKline split: a winning strategy?

GlaxoSmithKline split: a winning strategy?
Shareholders seem to like the GSK split proposal, with the price up strongly off the back of the news. But is the strategy as good as it seems? Here are two major considerations for investors.

Emma Walmsley can be forgiven for her previous lack of progress after nearly two years as chief executive of the UK’s biggest pharma company. She’s pulled off a whopper of a deal. Combining GlaxoSmithKline’s (GSK) consumer healthcare division with that of its US peer Pfizer (US: PFE) sounds sensible – both companies have struggled to generate decent returns from their sprawling portfolios. The conglomerate pharma business model seems antiquated in a time when healthcare pioneers are rolling out gene therapies which have the potential to cure cancer. Investors are undoubtedly pleased, with shares in GSK opening up 7% following the…

Sign up and read the full article

Register to continue reading this article.

Get FREE access now

Already a member? Login

Have your say

Log in or register to view or add comments.

Get free access now

Register free to gain access to more research


Investor's Champion Premium Content

Subscribers to our Premium Content receive priority notification by email of newly published research. Premium Content costs as little as £3.20 per research note.

More on Premium Content

More on GlaxoSmithKline

New Year, new you: profit from your resolutions

07/01/2019 · Investors Clinic
This January, thousands of us will drag ourselves into the gym, or spend our days craving…

GlaxoSmithKline split: a winning strategy?

19/12/2018 · Get Investing
Shareholders seem to like the GSK split proposal, with the price up strongly off the back…

Astra vs GSK. Drugs vs Dividends.

16/11/2018 · Blog
Update: AstraZeneca has failed another drugs trial. That's the risk of its strategy which has been…

More Get Investing

Avoid calamity - read the results


Batten down the hatches – it’s time to get defensive

Interserve: tough on tracker funds

06/02/2019 · Interserve